Vaccinia Tian Tan (VTT) was used as a vaccine against smallpox in China for millions of people before 1980, yet the biological characteristics of the virus remain unclear. We have characterized VTT with respect to its host cell range, growth properties in vitro, and virulence in vivo. We found that 11 of the 12 mammalian cell lines studied are permissive to VTT infection whereas one, CHO-K1, is nonpermissive. Using electron microscopy and sequence analysis, we found that the restriction of VTT replication in CHO-K1 is at a step before viral maturation probably due to the loss of the V025 gene. Moreover, VTT is significantly less virulent than vaccinia WR but remains neurovirulent in mice and causes significant body weight loss after intranasal inoculation. Our data demonstrate the need for further attenuation of VTT to serve either as a safer smallpox vaccine or as a live vaccine vector for other pathogens. D
Introduction
Smallpox is a deadly human disease that is caused by the infection of the variola virus, a member of the orthopoxvirus genus (Moss, 1991) . Because the mortality rate of smallpox is over 50%, millions of lives were lost to this disease over the last century before the introduction of an effective vaccine. Vaccinia virus is another member of the orthopoxvirus genus (Moss, 1991) . Since vaccinia virus has mutual immunogenicity with variola virus and only causes mild complications in humans, the use of the vaccinia virus as a smallpox vaccine enabled aggressive immunization promoted by the World Health Organization (WHO), which led to the declaration of complete variola eradication in the world by 1979 (Breman and Arita, 1980; Fenner, 1982; Mayr, 1999; Strassburg, 1982;  or http://www.who.int/emc/ diseases/smallpox/Smallpoxeradication.html).
The history of smallpox in China can be traced back to Han Dynasty (206-202 B.C.) (Ma, 1995) . The smallpox was not preventable until Chinese invented variolation in North Song Dynasty (960-1127 A.D.), which was probably the earliest practice of smallpox prevention (Ma, 1995) . By the time of Qing Dynasty (1644-1911 A.D.) , variolation was promoted in Kangxi reign to reduce the mortality in the imperial family (Chang, 1996) . Variolation was largely supplanted by Edward Jenner's cowpox vaccine discovered in 1798, but it was not officially proscribed till 1950s (Strassburg, 1982; Yutu et al., 1988) . When the smallpox vaccination program was interrupted, variolation was renewed in some remote areas in China which caused several outbreaks of smallpox in 1960s (Yutu et al., 1988) . During the smallpox eradication campaign in 1960-1970s, the most extensively used smallpox vaccine in China was the vaccinia Tian Tan (VTT) strain (Jin et al., 1997a (Jin et al., , 1997b . VTT exhibits good immunogenicity, moderate reactogenicity, and relatively mild complications in humans. Due to these natural properties, VTT was successfully used for millions of Chinese to prevent smallpox infection between 1920 and 1980, which subsequently led to the variola eradication in China before 1980 (http://www.who. int/emc/diseases/smallpox/Smallpoxeradication.html). Despite such extensive human use, however, many of the biological characteristics of the vaccine strain VTT remain unknown.
Recently, vaccinia virus attracted more attention for its re-use as a vaccine against variola virus, due to the rise in bio-terrorism threats around the world (Mahalingam et al., 2004; Weltzin et al., 2003) . This is a significant security concern because about 40% of people in the United States, for example, are younger than 30 years old and are not vaccinated. Moreover, vaccinia virus can also be engineered to deliver foreign antigens to serve as a live vaccine vector for other pathogens (Moss, 1996; Paoletti, 1996) . As an AIDS vaccine candidate, an attenuated modified vaccinia Ankara (MVA) expressing HIV-1 components has entered clinical trials (McMichael and Hanke, 2002) . Considering the potential future use of VTT in humans, we attempt to determine the biological properties of the virus.
Based on sequence analysis, VTT displays genetic features distinct from other vaccinia viruses, including the Western Reserve (WR) strain (Hou et al., 1985; Jin et al., 1997a; Tsao et al., 1986) . These data infer the plausibly distinct biological properties of VTT. In recent years, VTT was explored as a live vector for other pathogens such as rabies virus and hepatitis B virus (Guo et al., 2001; Zhu et al., 1996) . These studies, however, are still preliminary. Up to now, few data are available with respect to the baseline biological properties of VTT, which is essential for assessments of the safety and immunogenicity of a vaccinia expression vector (Meyer et al., 1991; Moss, 1996; Paoletti, 1996) . In this study, the smallpox vaccine VTT is studied in relation to its host range, growth properties, morphogenesis, and virulence. Our findings will serve as a baseline for further modification of the virus, as either a safer smallpox vaccine or a live vaccine vector for other pathogens.
Results

Host range of VTT strain
Twelve mammalian cell lines of various host origins and primary chicken embryo fibroblasts (CEF) were tested in this study (Table 1) . Using immunochemical staining, we found that each cell type tested can be infected by VTT. This is indicated by the expression of specific viral antigen stained with polyclonal anti-vaccinia serum in infected cells (Fig. 1) . Except for CHO-K1, all cell types show positive foci, which consist of a cluster of stained cells. However, the number of positive cells and the extent of cytopathic effects is different in each cell type. We scored the observed foci by counting the positive cells post-infection (pi) according to a method previously described (Table 1) (Carroll and Moss, 1997) . CHO-K1 is deemed nonpermissive since only individually positive cells were observed 24 h pi and the number of infected cells tended to decrease 48 h pi (Fig. 1) . In contrast, clear cytolytic effects and large plaques were found 48 h pi in eight permissive cell types including HeLa, MRC-5, Vero, COS-7, MDCK, RK13, C6, BHK-21, and primary CEF cells. Importantly, the growing size of each positive foci or plaque overtime in these cell types also suggests that the cell-cell contact is essential for viral transmission or spread. In particular, COS-7 cells show the most rapid cell killing (Fig. 1B) . Large plaques were frequently seen in COS-7 by 24 h pi. Vero cells seem to give the highest yield of (Carroll and Moss, 1997) . b Virus replication (fold increase in virus titer) determined by dividing the virus yield at 72 h by the practical input titer. Cell lines were therefore categorized into permissive (P, N25-fold increase) and nonpermissive (NP, b1-fold increase) cells (Carroll and Moss, 1997) . progeny virions reflected by the fold of viral replication reaching 562.5-fold by 72 h pi (Table 1) . Such titer is more than doubled than that of CEF (128.2-fold) which was used for VTT manufacture before 1980 (Table 1 ). The data suggest the potential use of Vero cell for manufacturing VTT virus in the future. For 293T and WISH cells, typical cytolytic plaques usually began to become predominant after 72 h pi, suggesting relatively slower cell killing in these cell types. In PK(15) cells, no severe cytolytic effects were found although small clusters of infected cells were identified, which may suggest a different cytopathic mechanism in this cell type. Moreover, the much fewer positive cells found in each foci at 48 h pi also indicated that the viral spread via cell-to-cell contact is less efficient in PK(15) cells.
Replication of VTT under low multiplicity of infection
To further understand the replication kinetics of vaccinia VTT in various cell types tested, we infected the cells at a low multiplicity of infection (moi). Using a 0.05 moi, we determined the growth of viral replication for multiple rounds (Carroll and Moss, 1997) . We found that VTT replicated with similar kinetics in four human cell lines including HeLa, MRC-5, 293T, and WISH ( Fig. 2A ). Since these cells were derived from human cervix epithelial, lung fibroblast, kidney epithelial, and amnion epithelial, respectively, VTT can replicate efficiently in cell types with diverse tissue origin. In these cells, the viral replication quickly reached peak level around 24-48 h pi ( Fig. 2A) . Interestingly, the cytolytic effects seem to occur quickly and more severe in MRC-5 cells, a fibroblast lineage (Fig. 1B) . This finding is consistent with the data generated in nine non-human cell types including Vero, COS-7, CHO-K1, BHK-21, MDCK, RK13, PK(15), C6, and CEF. VTT tends to replicate better and cause more severe cytopathic effects in cells of fibroblast lineage such as COS-7 and C6 regardless of the host origin ( Fig. 1B and Table 1 ). The similar growth kinetics of VTT found in several cell types makes it possible to use one of them to replace CEF cells for vaccine production (Fig. 2B) . Consistent with host range study, TT does not seem to replicate in CHO-K1 cells with the 0.05 moi for infection.
Replication of vaccinia VTT under high moi
A high moi usually results in synchronized infection in viral target cells. Since a synchronized infection predominantly reflects intracellular virus replication, we attempt to predict the number of infectious viral particles produced daily in each cell. In this experiment, the cells were infected with a high moi of 5. After infection, the cells were processed to measure the yield of viral production within 24 h. Under these conditions, we found that significant yields of VTT were obtained from the four human cell lines HeLa, MRC-5, 293T, and WISH (Fig. 2C ) as well as from many non-human cells including Vero, BHK-21, MDCK, RK13, COS-7, PK(15), C6, and CEF (Fig. 2D) . As expected, we did not see viral production in the non-permissive CHO-K1 cells (Fig. 2D) . The yield of viral particles in each cell type has been summarized in Table 2 . Considering the data of day 0 largely reflect the quantity of input virus, we have subtracted the values of day 0 for the calculation of viral yield for later time points. Generally, most cell types produced more than one plaque forming unit (PFU) of infectious VTT per cell except for CHO-K1 at 24 h pi (Table  2 ). Vero cells, on average, produced the highest amount of virus with an approximated ratio of about 29 virions per cell in 24 h pi (Table 2 ). Since Vero is currently used to produce human rabies and Japanese B encephalitis vaccines in China (Dong et al., 2002; Yan et al., 2002) , our findings have demonstrated the potential use of this cell line to produce VTT-based smallpox vaccine if needed. Of interest, all cell types tested, including the non-permissive CHO-K1 cell, exhibited severe cytopathic effects 24 h after VTT infection (Table 2 ). This finding indicated that VTT-infected cells may undergo cell death rapidly. Moreover, this finding also suggested that the blockade of viral replication in CHO-K1 cells may not be at the entry step because the observed cell death might be a result of viral infection.
Virus morphogenesis in permissive and non-permissive cells
To understand the blockade of viral replication in CHO-K1 cells, vaccinia VTT-infected cells were further subjected to electron microscope (EM) analysis. By analyzing the morphology of newly produced viral particles, we expected to understand the life cycle of VTT in CHO-K1 cells. For this reason, CHO-K1 and some permissive cells were analyzed by EM 16 h pi. As shown in Fig. 3A , no intracellular mature viruses (IMV) were found in infected CHO-K1 cells although some immature virions were frequently found in the cytoplasm of the infected cells. As controls, the majority of the VTT particles showed the characteristic brick-shape of IMV in the cytoplasm of permissive cells including RK13, Vero, and CEF (Figs.  3B-D) . Furthermore, viral particles at different stages of viral maturation, like spherical immature virions, were found in permissive cells as well (Figs. 3B-D) . Therefore, together with the finding of VTT-specific protein expression in individual CHO-K1 cells (Fig. 1B) , our data indicated that the aborted viral replication in this cell line is likely due to a blockade at the stage of viral assembly before maturation. Considering that cowpox V025 gene determines the virus growth in CHO cells (Ramsey-Ewing and Moss, 1995 Moss, , 1998 Spehner et al., 1988) , we have amplified the gene homolog from our VTT. We found that our sequence is 99.9% identical to the V025 gene sequence of VTT deposited in the GenBank (accession number AF095689). Moreover, we found that VTT sequences contain many similar mutations or deletions to WR strain when these sequences were compared with the cowpox sequence (AF482758) (data not shown). In particular, VTT and WR share a nucleotide deletion in the V025 gene which resulted in a reading frame shift and introduced a premature stop codon at amino acid position 72. Therefore, like the situation in WR, the loss of the functional V025 gene probably contributes to the replication failure of VTT in CHO-K1 cells.
Virulence of vaccinia VTT strain in BALB/c mice
Despite of the extensive use of vaccinia VTT in humans in the last century, the virulence of the virus has not been carefully determined. Here, we characterized the virulence of the VTT by inoculating the virus into BALB/c mice. The viral inoculums were based on the tissue infectious dose (PFU) as determined in Vero cells. We first determine the lethal dose (LD 50 and LD 90 ) of VTT by inoculating seven groups of mice via the intracranial route. Each of the seven groups, six mice per group, received one of 5-fold diluted VTT. We found that the LD 50 and LD 90 of VTT were 3.1 Â 10 3 PFU and 1.4 Â 10 4 PFU, respectively. The LD 50 of VTT, therefore, is about 300-fold less virulent in comparison to that of vaccinia WR strain published previously, which is about 10 PFU (Buller et al., 1985; Kutinova et al., 1995) . For a direct comparison, we also tested the LD 50 and LD 90 of WR using the same method. The infectious dose of WR was determined in Vero cells in parallel with VTT. Most mice died after received WR except for some mice in the group received 1 PFU of WR. We were able to obtain the LD 90 of WR which is 2.4 PFU. This LD 90 value indicates that WR is over 5000-fold more virulent than VTT strain (LD 90 = 1.4 Â 10 4 PFU). To further determine the replication kinetics of VTT in mouse brain, we inoculated 3 LD 50 of VTT into ten mice via the same intracranial route. Two animals were sacrifice daily for the titration of viral replication in their brains. As shown in Fig. 4 , VTT strain replicated in the mouse brain with a peak viral yield of 1.71 Â 10 4 PFU per brain on day 3 pi. Virus titer tended to decline on day 4 pi, yet the remaining animals died on day 5 pi. These data demonstrated that VTT is likely a neurovirulent virus.
The virulence of VTT was also tested by measuring the body weight change of infected mice after they were intranasally injected with viruses (Fig. 5) . In contrast to mock mice which received PBS, the infected mice showed clear dose-dependent weight loss starting from the third day after viral inoculation. There is a clear positive correlation between the dose of virus inoculation and body weight loss of the animals. A similar experiment was done by using the WR strain. We inoculated two groups of BALB/c mice with 10 3 and 10 4 PFU of WR, respectively, via the intranasal route. We found that 10 4 PFU of WR caused over 25% weight loss in BALB/c mice, which was very similar to the PFU of VTT. Mice were sacrificed daily, the intracranial contents were homogenized in PBS, and the titer of infectious virus was determined by a plaque assay on Vero cell monolayers. Each point on the curve represents the average value of two mouse brains. The error bar indicates the experimental variation. mice that received 10 6 PFU of VTT. Similarly, 10 3 PFU of WR resulted in comparable weight loss with 10 5 PFU of VTT in mice. This dose-dependent pattern is comparable to that of WR in mouse model published previously (Brandt and Jacobs, 2001 ). These results demonstrated that WR is about 100 more virulent than VTT when the virus was given via the intranasal route. Taken together, our data suggested that VTT is much less virulent than vaccinia WR strain although it remains to be neurovirulent.
Discussion
In this study, we have characterized the biological properties of the smallpox vaccine VTT strain by testing its host cell range, growth properties, and virulence. We found that VTT has a broad host cell range as the virus infected all 13 different cell types of divergent host origins. Various cell types, however, displayed different permissibility and efficiency in supporting VTT replication. Moreover, we found that VTT could productively replicate in the mouse brain and caused animal death after intracranial infection. VTT also caused loss of mouse body weight after intranasal infection. These findings indicated that VTT is a neurovirulent virus and that it will need further attenuation for future human use. Our data also established baseline biological profiles for future VTT studies.
VTT has a broad host cell range. The biological characteristics of multiple vaccinia strains have been previously characterized such as strains of parental Ankara, WR, Copenhagen, Wyeth, and Lister (Carroll and Moss, 1997; Kutinova et al., 1995; Meyer et al., 1991; Tartaglia et al., 1992) . One common property shared by these viruses is their broad host cell range. Before the present study, the host range of VTT was unclear despite the fact that the virus was given to millions of Chinese as a smallpox vaccine before 1980, which probably made VTT the most extensively used human smallpox vaccine in the world. Since VTT vaccination was quite effective against smallpox, the side effects related to the biological properties of VTT were probably ignored and not reported. Here, we found that VTT has broad cell tropism to enter all 13 cell types tested despite the virus was passaged on calf skin or CEFs for many generations during the production of smallpox vaccine (The Committee for Biological Product Standardization in China, 1979) . Thus, like many vaccinia viruses, VTT probably uses similar common receptor or mechanism to enter the broad range of target cells.
Despite of the broad host cell range, the replication kinetics of VTT varies among different cell types. VTT productively replicates in 12 of 13 mammalian or avian cells except in non-permissive CHO-K1 cells. The infected cells, however, displayed different efficiency in supporting the VTT replication. For example, Vero cell produced the highest yield of VTT whereas CHO-K1 cells only had abortive infection. The viral yield depends not only on the capability of each cell type to produce the progeny virions but also on the efficiency of viral spread among cells. The reason that Vero cells made the highest yield of virions is very likely due to the fact that each Vero cell could produce more virions than other cell types and VTT could spread among Vero cells quickly (Tables 1 and 2 ). Since Vero cells are currently used for human rabies, hepatitis A, and Poliovirus vaccines manufacture in China and other countries (Dong et al., 2002; Sampath et al., 2005; Sheets, 2000; Sun et al., 2004) , our data suggested that this cell type may be used to replace CEF to produce smallpox vaccine VTT for use against bio-terrorism. This replacement will eliminate the use of special pathogen free eggs and hence help minimize the chicken-derived pathogens and reduce the vaccine production cost substantially (Sheets, 2000) . However, we should also be cautious on other issues related to the use of Vero cells for vaccine production. For example, the specific Vero cell line recommended by WHO should be used to avoid the potential contamination with SV40 or some unexpected cellular proteins which may cause auto- immune reactions in humans (Monath et al., 2004; Sheets, 2000) . Using EM analysis, we found that the abortive infection of VTT in CHO-K1 cells is likely due to a blockade at viral maturation stage. Since this finding is consistent to the previous report on vaccinia Ankara and WR, there might be a common mechanism shared by these vaccinia strains with VTT (Carroll and Moss, 1997; Ramsey-Ewing and Moss, 1995; Spehner et al., 2000) . There are several possible factors related to the abortive viral replication in CHO-K1 cells. First, some host cell proteins, which are essential for viral maturation, might be missing in CHO-K1 cells. Second, due to the loss of V025 gene by our sequence analysis, the shutoff of some vaccinia intermediate and late protein synthesis in CHO-K1 cells might lead to the aborted viral maturation (Ramsey-Ewing and Moss, 1995 Moss, , 1998 . Third, some viral genes D13L, A14L and A17L might also play a role in the morphogenesis of vaccinia virus (Rodriguez et al., 1997; Smith et al., 2002; Wolffe et al., 1996) . The exact mechanism, however, remains to be further studied for VTT.
VTT is a neurovirulent vaccinia stain. To make a vaccinia-based human vaccine, the safety profile of the virus is one of the most essential elements (Meyer et al., 1991; Tartaglia et al., 1992) . Based on previous reports, the LD 50 of other vaccinia strains, such as Copenhagen and Wyeth, was about 10 4 PFU by intracranial route in mice (Kutinova et al., 1995; Tartaglia et al., 1992) . Similarly, we found that the LD 50 of VTT is 3.1 Â 10 3 PFU. However, if we compare with the neurovirulent WR strain which has a LD 90 of 2.4 PFU, VTT is about 5000-fold less virulent with a LD 90 of 1.4 Â 10 4 PFU. Nevertheless, VTT was able to replicate in mouse brain with growth kinetics somewhat similar to that of vaccinia Wyeth (Lee et al., 1992) . Moreover, VTT infection resulted in over 25% body weight loss in BALB/c mice after 10 6 PFU of VTT was intranasally inoculated. In comparison, only 10 4 PFU of WR (100-fold less than VTT) was needed to cause similar body weight loss in vivo. Taking together these findings, we conclude that although weaker than WR strain VTT remains to be a neurovirulent vaccinia strain. If VTT is produced as vaccines for future human use, further attenuation of the virus should be considered. This is a serious concern because VTT may be lethal to humans especially to immune-compromised patients who often fail to control systemic vaccinia replication.
VTT may be engineered to become a safe live-attenuated vaccine vector. Currently, several highly attenuated vaccinia strains have been developed as live viral vectors to make vaccines for other pathogens including human immunodeficiency virus (Moss, 1996) . In this study, we have established the biological profile of VTT which may serve as a baseline for future modification of the virus. Previously highly-attenuated modified vaccinia Ankara (MVA) strain was successfully obtained by serial passages of its parental virus in CEF cells (Mayr et al., 1975 (Mayr et al., , 1978 . Similar strategies have also been used to attenuate VTT through serial passages of the virus on chick embryos or on human diploid cells (Yang et al., 1979; Zhao et al., 1981) . Given no biological characterization was reported on the passaged VTT virus, we do not know to what extent those viruses have been attenuated. After some host range and virulence genes were identified from the genome of vaccinia virus, the introduction of selected deletions in viral genome has become another approach to attenuate vaccinia virus (Mackett et al., 1985; Ramsey-Ewing and Moss, 1995; Tartaglia et al., 1992) . This approach became possible for VTT after the entire genomic structure of the virus was documented (Jin et al., 1997a) . Some preliminary results have indicated that removing thymidine kinase gene or C-K genomic may reduce the virulence of VTT (Li et al., 1999; Zhu et al., 1996) . These works showed some promising progress yet the detailed biological characteristics on the attenuated virus remain unknown. Considering the extensive and successful human use of VTT against smallpox in the history, we believe that understanding the biological properties of VTT is one of the fundamental steps for understanding the basis of the virus and for developing a safe human vaccine (Katz and Moss, 1997; Smith et al., 2002; Spehner et al., 2000; Weltzin et al., 2003) .
Materials and methods
Cells and virus
Twelve cell lines (Table 1) were grown under conditions suggested by the American Type Culture Collection (ATCC, Rockville, MD). The primary chick embryo fibroblasts (CEFs) were prepared from 10-day-old chicken embryos. The first generation of passaged CEF cells was used for virus infections. VTT 761 strain was obtained from the Institute of Virology, the Chinese Academy of Preventive Medicine. Vaccinia WR strain was obtained from ATCC (ATCC VR-1354, Rockville, MD). VTT and WR were propagated in Vero cells. Viral stocks purified through centrifugation over 36% sucrose cushion were used for in vitro experiments while those used for in vivo testing were further purified through sucrose density gradient centrifugation (Joklik, 1962) . Viral titers of VTT and WR were determined on Vero monolayers by plaque assay using crystal violet staining.
Immunostaining of virus plaques
Polyclonal anti-TT serum was produced in rabbits. This antibody was used to detect virus-infected plaques or foci. Two rabbits were immunized intradermally with 10 7 PFU of VTT. Four weeks after, these rabbits were boosted twice with 10 7 PFU of the purified TT stocks at a 3-week interval. The animal was bled 4 weeks after the final inoculation. The titer of anti-TT antibody in serum was determined in Vero cells by a plaque reduction neutralization assay.
For the test of cell-to-cell spread, plaques or foci of VTT were immunostained by the rabbit anti-VTT serum using a method previously described (Carroll and Moss, 1997) . The target cells were grown in 350-mm culture dishes to 90-100% confluence and then infected with TT stocks at a multiplicity of infection (moi) of 0.01. After absorption for 90 min, cells were washed three times with culture medium and then incubated at 37 8C for another 24 h or 48 h before immunostaining. After the incubation, cells were fixed with a cold 1:1 solution of methanol/acetone for 2 min and then incubated for 1 h at room temperature with antiserum diluted (1:80) with phosphate buffered saline (PBS) containing 2% fetal bovine serum (FBS). Cells were washed and then incubated for 1 h at room temperature with Protein A conjugated to horseradish peroxidase (Zhongshan Biotech; 1: 1500 dilution). After wash, the color was developed by incubation up to 30 min with substrate solution consisting of 10 Al of 30% H 2 O 2 and 0.2 ml of an ethanol solution saturated with dianishidine (Sigma) in 10 ml of PBS.
Virus replication in vitro
Cells were grown in Falcon 24-well culture dishes to form monolayers. The number of cells was calculated before the virus inoculation so as to determine the input amount of virus. VTT was then applied onto the cell monolayers at an moi of 0.05 in 100 Al of medium containing 3% FBS. After 90-min incubation at 37 8C, cells were washed three times with medium containing 3% FBS and replenished with fresh culture medium. After wash, cells and supernatant were harvested at 0, 24, 48, and 72 h pi. For one step growth curves, cells were infected with an moi of 5. The samples were harvested at 0, 12, and 24 h pi. After freeze-thawing thrice, the viral titers were determined in duplicates on Vero cells.
Electron microscopic analysis
Confluent cell monolayers were infected with 5 moi of VTT. The virus was allowed to adsorb for 90 min at 37 8C. The cells were then washed with medium three times and incubated at 37 8C for an additional 16 h. Cells were then trypsinized off the culture plates and washed with PBS twice through centrifugation at 1200 rpm for 10 min. Then the cell pellets were fixed in 2.5% glutaraldehyde and processed for transmission electron microscopy using a routine technique described previously (Wolffe et al., 1996) .
Virulence in BALB/c mice
Groups of six 3-to 4-week-old BALB/c mice (equal gender) were inoculated intracranially with one of 5-fold diluted VTT or WR virus in 10 Al of sterile PBS. The LD 50 was determined by the number of mice that succumbed between 1 and 14 days pi by calculating the 50% end point using the Reed-Muench method (Reed and Muench, 1938) .
With respect to VTT replication in mouse brain, 3-to 4-weekold mice were inoculated intracranially with 1.1 Â 10 4 PFU (3LD 50 ) of purified virus in 10 Al of PBS. Two of tested mice were sacrificed daily, and their brains were homogenized in PBS before they were subjected to viral titration.
The virulence of VTT in mice was also studied by their weight loss after viral inoculation using a method previously described (Zhang et al., 2000) . Groups of five 5-week-old BALB/c mice were inoculated intranasally with 0, 10 4 , 10 5 , and 10 6 PFU of VTT in 30 Al of PBS. For comparison, 5-week-old BALB/c mice were inoculated with 10 3 or 10 4 PFU of WR under the same conditions, respectively. The body weight change of each mouse was monitored daily and the mean value was used in the graph of the weight loss curve.
